Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression
Status:
Terminated
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are to evaluate if switching an antiretroviral medication from
efavirenz (EFV) to atazanavir/ ritonavir (ARV/r) will, in a 96-week period, change:
1. the amount of fat in HIV patients with lipoatrophy,
2. metabolic lab values such as your lipid (fat) profile, glucose (blood sugar), and
insulin (a hormone that regulates glucose) in HIV patients with lipoatrophy.
Phase:
Phase 4
Details
Lead Sponsor:
The Cleveland Clinic
Collaborators:
Bristol-Myers Squibb Case Western Reserve University National Institute of Allergy and Infectious Diseases (NIAID)